NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO U.S. PERSONS OR INTO OR IN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
This announcement is an advertisement and not a prospectus. Any decision to invest in any securities referred to in this announcement must be made exclusively on the basis of the prospectus published by the Company on 3 November 2015, and any supplement thereto, in connection with, inter alia, the admission to trading of the entire issued share capital of the Company to the Specialist Fund Market of the London Stock Exchange and the creation of a placing programme (the "Placing Programme") of ordinary shares of no par value in the capital of the Company (the "Prospectus"). A copy of the Prospectus is available for inspection at www.morningstar.co.uk/uk/NSM. This announcement does not constitute a recommendation regarding any securities. This announcement contains inside information.
30 September 2016
Axiom European Financial Debt Fund Limited
Result of Placing
Further to the announcement dated 28 September 2016, the board of directors of Axiom European Financial Debt Fund Limited (the "Company") is pleased to announce that approximately £6 million of gross proceeds have been raised under the placing of new ordinary shares. Accordingly, 6,247,542 new ordinary shares (the "New Shares") will be issued at the placing price of 96.5 pence per share.
Application has been made to the London Stock Exchange for the New Shares to be admitted to trading on the London Stock Exchange ("Admission"). It is expected that Admission will become effective and that dealings in the New Shares will commence on 4 October 2016.
Following Admission, the total number of ordinary shares in issue will be 60,930,764, and the total number of voting rights in the Company will be 60,930,764. There are no shares held in treasury. The above figure of 60,930,764 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Disclosure and Transparency Rules.
For further information please contact:
Axiom Alternative Investments SARL
David Benamou, Managing Partner
Jerome Legras, Managing Partner
Tel: + 44 (0)20 3807 0670
Liberum (Sole Bookrunner)
Shane Le Prevost / Richard Crawley / Richard Bootle / Henry Freeman
Tel: +44 (0)20 3100 2222
MHP Communications (Financial PR Adviser)
Reg Hoare / Giles Robinson / Ollie Hoare
Tel: +44 (0)20 3128 8100
Members of the public are not eligible to take part in the Placing. This announcement and the terms and conditions referred to herein are directed in the United Kingdom only at persons selected by Liberum who are "investment professionals" falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FPO") or "high net worth companies, unincorporated associations etc." falling within Article 49(2) of the FPO, or persons to whom it may otherwise be lawfully communicated (all such persons together being referred to as "Relevant Persons"). This announcement and the terms and conditions referred to herein must not be acted on or relied on in the United Kingdom by persons who are not Relevant Persons. Any investment or investment activity to which this announcement relates is available only to, and will be engaged in only with, persons in the United Kingdom who are Relevant Persons.
The New Shares that are the subject of the Placing are not being offered or sold to any person in the European Union, other than to "qualified investors" as defined in Article 2.1(e) of Directive 2003/71/EC.
This announcement is not for distribution, directly or indirectly, in or into the United States of America (including its territories and possessions, any state of the United States of America and the District of Columbia) (the "United States"), Australia, Canada, Japan or South Africa or into any other jurisdiction where applicable laws prohibit its release, distribution or publication. This announcement does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase, any securities in the United States, Australia, Canada, Japan or South Africa or in any other jurisdiction where such offer or sale would be unlawful. The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the US Investment Company Act of 1940, as amended and may not be offered or sold directly or indirectly in or into the United States or to or for the account or benefit of any US Person (within the meaning of Regulation S under the Securities Act). The securities referred to herein have not been registered under the applicable securities laws of Australia, Canada, Japan or South Africa and, subject to certain exceptions, may not be offered or sold within Australia, Canada, Japan or South Africa or to any national, resident or citizen of Australia, Canada, Japan or South Africa.
This announcement has been issued by and is the sole responsibility of the Company. No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by, Liberum or by any of its affiliates or agents, as to or in relation to the accuracy or completeness of this announcement or any other written or oral information made available to or publicly available to any interested party or their advisers and any liability therefore is expressly disclaimed.
Liberum, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting as sole bookrunner to the Company and is acting for no-one else in connection with the Placing and the contents of this announcement and will not be responsible to anyone other than the Company for providing the protections afforded to clients of Liberum or for providing advice in connection with the Placing and the contents of this announcement or any other matter referred to herein.
This information is provided by RNS